1. Ackerman, D. M., Blumberg, A. L., McCafferty, J. P., Sherman, S. S., Weinstock, J., Kaiser, C, and Berkowitz, B., 1983, Potential usefulness of renal vasodilators in hypertension and renal disease: SK&F 82526, Fed. Proc. 42:186–190.
2. Andén, N.-E., Golembiowska-Nikitin, K., and Thornström, U., 1982, Selective Stimulation of dopamine and noradrenaline autoreceptors by B-HT 920 and B-HT 933, respectively, Naunyn Schmiedebergs Arch. Pharmacol. 321:100–104.
3. Anderson, K., Kuruvilla, A., Uretsky, N., and Miller, D. D., 1981, Synthesis and pharmacological evaluation of sulfonium analogs of dopamine: Non-classical dopamine agonists, J. Med. Chem. 24:683–687.
4. Andrews, C D., Davis, A., Freeman, H. S., McDermed, J. D., Poat, J. A., and Woodruff, G. N., 1978, Effects of ( + )-and (-)-enantiomers of 2-amino-6,7-dihydroxy-l,2,3,4-tetrahydronaphthalene on dopamine uptake, Proc. Er. Pharm. Soc. 1978:433P.
5. Arana, G. W., Baldessarini, R. J., and Neumeyer, J. L., 1983, Structure-activity characteristics for high affinity dopamine-agonist binding at central dopamine receptors, Acta Pharm. Suec. [Suppl.] 2:25–36.